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Background and Objective. Using Collagen IV staining, we have previously reported that the reticular basement membrane (Rbm)
is hypervascular and the lamina propria (LP) is hypovascular in COPD airways. This study compared Collagen IV staining with
vessels marked with anti-Factor VIII and examined vessel permeability in bronchial biopsies from COPD and normal subjects
using albumin staining. Results. Anti-Collagen IV antibody detected more vessels in the Rbm (P = 0.002) and larger vessels in
both Rbm (P<0.001) and LP (P = 0.003) compared to Factor VIII. COPD airways had more vessels (with greater permeability)
in the Rbm (P = 0.01) and fewer vessels (with normal permeability) in the LP compared to controls with both Collagen IV and
Factor VIII antibodies (P = 0.04 and P = 0.01). Conclusion. Rbm vessels were increased in number and were hyperpermeable in
COPD airways. Anti-Collagen IV and anti-Factor VIII antibodies did not uniformly detect the same vessel populations; the ﬁrst is
likely to reﬂect larger and older vessels with the latter reﬂecting smaller, younger vessels.
1.Introduction
Angiogenesis is under vigorous study in many diseases in-
cludingchronicinﬂammationandmalignancies.Chronicin-
ﬂammatory diseases of the airways such as asthma and
COPD are no exceptions [1, 2].
For better detection of blood vessels, speciﬁc stains are
needed as haematoxylin and eosin alone are not speciﬁc
enough [3]. The most commonly used tissue vessel markers
in studies of the respiratory tract have been antibodies
against Collagen IV and Factor VIII, CD31 (EN-4) and
CD34. Both glycol methacrylate (GMA) processing and par-
aﬃn embedding are superior to other methods for investiga-
tion of vessels in tissue samples [4].
FactorVIIIantigenisproducedbyendothelialcellsandis
physiologically involved in platelet aggregation and adhesion
[5, 6] .An u m b e ro fs t u d i e sh a v er e p o r t e dF a c t o rV I I Ia n t i -
body as a reliable marker for blood vessel detection [7].
However, it has been reported that Factor VIII antibody also
stains megakaryocytes, mesenchymal tissue, and immune
cells in addition to endothelial cells [4, 8]. The eﬃciency of
FactorVIIIantibodyfordetectingbloodvesselshasalsobeen
shown to be related to the size of vessels [9, 10].
Our group has had substantial experience in using
Collagen IV antibody as a blood vessel marker in bronchial
biopsies (BB) [2, 11–14]. Collagen IV antibody delineates
endothelial basement membrane [3, 4].
An optimal marker for blood vessels should be speciﬁc,
independent of pathological changes in tissue (e.g., inﬂam-
mation, malignancy, hypoxia, ischemia, shearing stress), re-
sistanttotheusualmethodsoftissueﬁxationandprocessing,
open to detection of a variety of sizes (i.e., large and small)
and ages (i.e., old and new) of vessels, and be able to detect
diﬀerent types of vessels, that is, capillary, vein, arteriole,
and artery. It has been shown that under both physiological
and pathological conditions, endothelial cells modify their
antigen presentation [10], and most available histochemical
markers do not fully meet these characteristics, but the pros
and cons of diﬀerent immunohistologic antibody systems
have not been worked out in any detail.2 Journal of Allergy
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Figure 1: Vessels in the bronchial mucosa. Bronchial biopsies taken from the same current-smoking COPD subject, ×400. Vessels (black
arrows)arestainedwithanti-CollagenIVantibody(a)andanti-FactorVIIIantibody(b).Alargevesselwhichcontactsthereticularbasement
membrane (Rbm, arrowheads) is indicated by white arrows. The epithelium is thickened, probably because of chronic smoking exposure.
Antibodies to Collagen IV and Factor VIII stain diﬀerent
epitopes and indeed diﬀerent structures in vessels, and the
literatureindicatesthatthesemarkersforimmunostainingof
vessels do not uniformly detect vessels of diﬀerent sizes and
can vary in eﬃciency in pathological processes. Therefore,
we decided to compare the utility of anti-Collagen IV and
anti-Factor VIII antibodies as markers for blood vessels in
BB from COPD versus normal subjects and investigate what
the diﬀerences are in the vessel proﬁles that they stain. Based
on our previous ﬁndings [1, 2], we would expect any results
in this study to apply generally to smokers as well as COPD.
Permeability of mucosal vessels in asthma has been
reported to be increased and to correlate with clinical dete-
rioration [15]. Vascular endothelial growth factor (VEGF)
increases vascular permeability to blood water along with
proteins [16]. We have reported increased vessel-related
VEGF in the Rbm of COPD airways with the changes most
marked for current smoking COPD patients [2]. Therefore,
it is also reasonable to study vessel leakiness in the Rbm of
bronchial wall in current smoking COPD subjects.
2.MaterialandMethods
This was a cross-sectional study. Subjects were recruited
by advertisement. The study was approved by the Human
Research Ethics Committee (Tasmania) Network, and all sub-
jects provided written informed consent. Twenty-eight mild
to moderate COPD subjects and eight normal nonsmoking
controlsparticipated.COPDwasdiagnosedusingGOLDcri-
teria [17]. Subjects with other respiratory diseases including
aclinicalhistoryofasthmawereexcluded.AllCOPDsubjects
were on short-acting anticholinergic bronchodilators only.
Lung function tests were performed according to ATS/ERS
guidelines [18]. Fiberoptic bronchoscopies and endobronchial
biopsies were performed as previously described [2]. There
were no complications from the procedures.
2.1. Tissue Processing. 2 × paraﬃn-embedded sections of
3μma n d5 0 μm apart mounted on APTS-coated slides
were used. Following dewaxing and hydration, sections
Table 1: Demographics.
Group
Control
(n = 8)
COPD
(n = 28)
Age∗, median (interquartile range), years 54 (9) 61 (10)
Gender†,f e m a l e( n u m b e r ) 2 9
Pack-year smoking history, median
(interquartile range) 0 47 (23)
FEV1/FVC%¶, median (interquartile range) 79 (17) 57 (16)
∗P = 0.1 (Mann-Whitney test).
†P = 0.2 (Fisher’s Exact test).
¶P<0.001.
were subjected to heat retrieval using Dako S1700 for 20
minutes (except Albumin which did not require epitope
retrieval), and then endogenous peroxidase was quenched
using 3% hydrogen peroxide for 15 minutes. Sections were
incubated in primary antibodies for either Von Willebrand
factor (Factor VIII-related antigen) (Dako M06160), Type
IV collagen (Dako M0785) (both at 1:150 for 90 minutes)
(Figure 1), or Albumin (Abcam Ab 2406) 1/6000 for
30 minutes at 20 degrees Celsius. For negative controls,
matched sequential sections were stained with primary
antibody, replaced with a species-appropriate IgG1 isotype,
at equivalent dilutions and conditions. A horseradish
peroxidase (HRP) conjugated DAKO Envision plus (Dako
K4001) reagent was used for secondary antibody binding
andDABPLUS(DAKOK3468)forcolorresolution(brown).
Mayer’s haematoxylin counterstain was used to elaborate
nuclei. Sections were dehydrated in ethanol, cleared in
xylene, and mounted in Permount prior to analysis.
Measurementswere performed using a computer-assisted
image analysis tool (Image-Pro version 5.1, Media Cybernet-
ics, USA). Pictures of all intact and nonoverlapping areas
were taken from each slide, and eight separate ﬁelds were
chosenrandomlyformeasurementstohaveonaverage3mm
of the Rbm in our measurements as we did in our previous
report [2].Thehistologist (AS)whoperformedthemeasure-
mentswasblindedtothediagnosesandorderofslides,which
had been independently randomly sorted and coded.Journal of Allergy 3
Table 2: Agreement between two methods of vessel staining in both groups together.
Mean, Collagen IV Mean, Factor VIII Mean of diﬀerences∗ 95% LoA†
Number of vessels/mm Rbm 8.5 4.8 +3.7 −10.2, +17.6
Area of vessels/mm Rbm 803 357 +446 −995, +1887
MVS of Rbm vessels, μm2/number 98 73 +25 −143, +193
Number of vessels/mm2 LP 313 356 −43 −333, +247
Area of vessels μm2/μm2 of LP × 100 5.7 4.2 +1.5 −4.4, +7.4
MVS of LP vessels, μm2/number 212 133 +79 −184, +342
∗Calculated as measurements with Collagen IV minus measurements with Factor VIII antibody.
†LoA: limits of agreement (mean ±2 standard deviation).
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Figure 2: Bland and Altman plots for number of vessels and mean vascular size (MVS) in the reticular basement membrane (Rbm) and
lamina propria (LP) in all study subjects together. Bland and Altman plots illustrate agreement between the two methods of vessel staining
with anti-Factor VIII and anti-Collagen IV antibodies. Values on the X axis represent means of the two measurements; values on the Y axis
indicate measurements with Collagen IV staining minus measurements with Factor VIII staining (C4-F8). The broken line represents the
meandiﬀerence.BoldlinesindicateLimitsofagreements(meanofdiﬀerences ±2standarddeviations).C4:anti-CollagenIV;F8:anti-Factor
VIII.
To be constant, we used the same methods for mea-
surements so as to be able to compare the results of this
current study with our previous report [2]. Vessels in the
reticular basement membrane (Rbm) and down to a depth
of 150μm of the subepithelial lamina propria (LP) from the
antilumenal margin of the Rbm were measured separately.
Only well-formed cylindrical or tubular structures that were
stained with immunostaining antibodies were measured
as vessels to avoid including nonvascular cells in analyses
(Figure 1). Number and cross-sectional area of vessels were
measured. These data were normalized by dividing by the
length of the Rbm or dividing by the surface area of the LP
examined. Mean vascular size (MVS) was calculated as total
vascular area/number of vessels. The area of the LP excluded
mucous glands and muscle.
For vessel permeability, using Image-Pro 5.1 again,
the percentage of compartment tissue area stained for
albumin was measured separately in the Rbm and LP in
current smoking COPD and normal controls and the results
expressed as a percentage (μm2 of tissue stained/μm2 tissue4 Journal of Allergy
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Figure 3: Bland and Altman plots for number of vessels and mean vascular size (MVS) in the reticular basement membrane (Rbm) and
lamina propria (LP) in COPD subjects. Number of vessels is expressed as No/mm Rbm and No/mm2 LP. MVS is presented as area μm2/No.
For MVS in the LP, the agreement between the two methods was best when vessels were relatively smaller and the diﬀerences increased as
MVS increased, with anti-Collagen IV showing larger MVS than anti-Factor VIII. Description of the measurements and abbreviations are
presented in Figure 2.
examined ×100). Finally, the percentage area of perivascular
albumin staining was measured within the 10μm perimeter
around vessels (to avoid overlapping of areas) in both
the Rbm and LP. We have previously successfully used
this method to measure vascular permeability in asthmatic
airways [15].
2.2. Statistical Analyses. The data from the two methods of
vessel staining were tested for agreement using the method
reportedbyBlandandAltman[19].Verybrieﬂy,bythislatter
method, the means of the two measurements are plotted
against the diﬀerences between the two measurements. The
95% limits of agreement (LoA = mean of diﬀerences ±2
standard deviations (SD) of diﬀerences) were calculated for
every measurement.
For comparison of means between two groups or
between two methods of staining, Student’s t-test was used
for variables with normal distribution and the Mann-
Whitney test for nonnormally distributed variables. Fisher’s
Exact test was used to compare gender distribution between
two groups. All continuous data were presented as median
(interquartile range), except for the data that are included
in agreement between the two methods of vessel staining
which were presented as mean ±2 standard deviations. P
value less than 0.05 was considered as signiﬁcant. SPSS 16.0
was used for statistical analyses. Pearson’s or Spearman tests
were used to test correlations for normally and nonnormally
distributed variables, respectively. SPSS 16.0 was used for
statistical analyses.
3. Results
Thirty-six subjects participated in the study. Table 1 sum-
marizes the demographics. The 28 COPD subjects were
balanced between 15 current smokers and 13 ex-smokers.
There were no signiﬁcant diﬀerences between groups in age
or gender.
3.1.CollagenIVversusFactorVIII. Themostimportantchar-
acteristics of agreement between the two methods of vessel
staining are summarized in Table 2. Bland and Altman plots
showthatanti-CollagenIVantibodydetectedhighernumber
of vessels and larger MVS in the Rbm and lower number
of vessels but again larger MVS in the LP compared with
anti-Factor VIII antibody in all study groups (Figure 2). This
was also the case for the COPD group analyzed separately
(Figure 3). For Bland and Altman plots, values on the Y axis
in Figures 2 and 3 were calculated as measurements withJournal of Allergy 5
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Figure 4: Comparison of the number, area, and MVS of vessels in the reticular basement membrane (Rbm). In both COPD and normal
groups, Collagen IV staining outlines more vessels of larger caliber, than Factor VIII staining. MVS: mean vascular size (area μm2/No); C4:
anti-Collagen IV antibody; F8: anti-Factor VIII antibody.
Collagen IV staining minus measurements with Factor VIII
staining.
Comparing the means of the absolute number, area and
MVS of Rbm vessels stained by the two immunostaining
methods conﬁrmed our results with the Bland and Altman
plots;thereweresigniﬁcantlygreaternumber,area,andMVS
of vessels with anti-Collagen IV antibody than with anti-
Factor VIII antibody both when all subjects were tested
together and when the COPD group was tested alone
(Figure 4). In the LP, comparison of the means showed that
the diﬀerences between two methods of blood vessel staining
were signiﬁcant for area and MVS but not for the number of
vessels (Figure 5).
3.2. COPD versus Normal Controls. When COPD subjects
were compared to controls, COPD had signiﬁcantly more
vessels in the Rbm and fewer vessels in the LP with both Col-
lagen IV and Factor VIII antibody staining (Figures 6 and 7).
Signiﬁcantly, more tissue was stained for albumin in
the Rbm in current smoker COPD than controls (median
(interquartile range), μm2/μm2 presented as percent, 0.37%
(1.68) versus 0.00% (0.20), P = 0.02). But perivascular6 Journal of Allergy
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Figure 5: Comparison of the number, area, and MVS of vessels in the lamina propria (LP). In both COPD and normal groups, Collagen IV
staining outlines bigger vessels but not more vessels. MVS: mean vascular size (area μm2/No); C4: anti-Collagen IV antibody; F8: anti-Factor
VIII antibody.
albumin in the Rbm or LP and albumin staining in the LP
were not signiﬁcantly diﬀerent between two groups.
3.3. Correlations. Number of Rbm vessels stained with anti-
Factor VIII antibody correlated negatively with forced vital
capacity (FVC) only in ex-smokers with COPD (Spearman
r =− 0.8, P = 0.002). Otherwise, there were no corre-
lations between our anatomical ﬁndings and lung function
parameters. We did not ﬁnd any suggestion of a relationship
between either age or pack-years smoking and vascular or
permeability changes in the COPD group.
4. Discussion
This study showed that anti-Collagen IV antibody tends to
stain more vessels in the Rbm and bigger vessels overall in
both the Rbm and LP, while anti-Factor VIII antibody stains
relatively smaller vessels. It has previously been shown that
vessel markers can have diﬀerent sensitivity and speciﬁcity in
detecting vessels in normal versus abnormal conditions. For
example, factors such as genetic diversity in endothelial cells,
hypoxemia, age, and shearing stresses have eﬀects on the
expression of Factor VIII protein [10, 20, 21]. The sensitivity
and speciﬁcity of these markers are also related to the sizeJournal of Allergy 7
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Figure 6: Comparison of reticular basement membrane (Rbm) vessels in COPD and normal control groups. COPD subjects have more
vessels with both methods of staining. MVS: mean vascular size (area μm2/No).
of vessels [9, 22]. Indeed, our data are consistent with a
previous report showing that staining for Factor VIII cannot
detect larger-sized vessels as accurately as smaller ones in
invasive breast cancer [9]. But this type of diﬀerentiation
has not previously been attempted with airway wall samples;
althoughourpreviousworkdidshowthattherewasashiftto
greater number and smaller vessels in the LP in asthma [14].
Anti-Collagen IV antibody consistently detected larger
vessels in the Rbm than Factor VIII antibody. In the LP, the
agreement between the two methods was best when vessels
were relatively smaller, so that as the MVS increased, there
were increasing diﬀerences between the two methods, with
anti-Collagen IV again demonstrating larger MVS than anti-
Factor VIII (Figures 2 and 3). The literature would suggest
that smaller vessels are likely to be disproportionately new-
er vessels, while larger vessels are likely to be older and
more mature or even “post-mature” ghost vessels [23–25].
An in vivo study on mice showed that new vessels in air-
ways, formed under angiogenic stimulation by VEGF, had
detectable pericytes and basement membrane by day 7.
When the newly formed vessels were deprived of VEGF,
ﬁrstly the ﬂow of blood stopped, followed by death and then
fragmentation of endothelial cells, and ﬁnally apoptosis of
pericytes. However, a basement membrane sleeve from the
whole structure remained for some time [23]. This empha-
sizes that diﬀerent markers will demonstrate vessels bett-
er or worse depending on their age, maturity, and growth
factor environment. We would propose that in conditions8 Journal of Allergy
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Figure 7: Comparison of lamina propria (LP) vessels in COPD and normal controls. Vessel number is decreased in COPD with both
methods. MVS: mean vascular size (area μm2/No).
w h e r ew ee x p e c ta c t i v en e wv e s s e lf o r m a t i o n ,s u c ha sa c t i v e
asthma or malignancies, anti-Factor VIII antibody may
detect these newer vessels better than anti-Collagen IV anti-
body. This could also be potentially useful in evaluating the
eﬀects of treatments on vascular regression, for example, the
eﬀects of inhaled corticosteroids on vessels in the airways
[13]. In contrast, vessels which are larger and probably
older are more eﬀectively detected when stained with anti-
Collagen IV antibody rather than with anti-Factor VIII anti-
body. On this basis, however, we cannot explain why the
number of Rbm vessels is signiﬁcantly increased with anti-
Collagen IV compared to anti-Factor VIII antibody; we
rather expected the data to be the other way round, that is,
more new and younger vessels. We suggest that this could be
the result of a high number of aged vessels with well-formed
endothelial basement membrane where the endothelium has
suﬃciently matured to lose its Factor VIII antigens.
A novel and especially interesting ﬁnding of this study
was increased leakiness of the vessels in the Rbm in current
smoking COPD. However, in contrast to our hypothesis,
we did not ﬁnd a correlation between albumin staining in
the Rbm and vessel-associated VEGF (data obtained in our
previous study [2]). Leak of plasma and its protein material
could provide an appropriate environment for angiogenesis
by extravasation of ﬁbrinogen and formation of a ﬁbrin
gel. Endothelial cells and other mesenchymal cells can easily
settle and grow in this environment [26]. Therefore, this
ﬁnding is compatible with the hypervascularity of the RbmJournal of Allergy 9
we have demonstrated in COPD. The consequence of having
leaky vessels just below the epithelium in COPD is ripe for
speculation and further study, but, at the very least, it may
contribute to ﬂuid and protein ﬂux into the airway lumen
and add to the mucus volume and constituents. This has
never previously factored into the concepts of the pathogen-
esis of smoking-related airway disease pathophysiology.
Both Collagen IV and Factor VIII immunostaining of
bronchial biopsies in this study conﬁrmed our previous
ﬁndings of hypervascularity of the Rbm and hypovascularity
of the LP in the COPD group compared to the control group
[2]. The negative correlation between FVC (likely to reﬂect
predominantly small airway narrowing) and Rbm vessels
emphasizes the potential functionally detrimental eﬀect of
vascular remodeling in the bronchial mucosa in COPD.
5. Conclusions
Larger and probably more mature vessels were detected bet-
ter by anti-Collagen IV antibody, while smaller and probably
newer vessels were detected better by anti-Factor VIII anti-
body. Increased permeability of vessels in the Rbm of current
smoking COPD subjects could be related to the hypervas-
cularity of this compartment and add to its potential func-
tional signiﬁcance. Both anti-Factor VIII and anti-Collagen
IV antibodies conﬁrmed hypervascularity of the Rbm and
hypovascularity of the LP in the COPD bronchial mucosa
compared to normal.
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